Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04306965 · ClinicalTrials.gov registry record · Phase 2
Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab
A Phase 2 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04306965 is a Phase 2 study that has completed, run by Tufts Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT04306965, a Phase 2 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Open label phase 2 investigational study of efficacy and safety of apremilast 30 mg twice a day (BID) in chronic atopic dermatitis when added to the FDA approved treatment dupilumab for atopic dermatitis that is not providing adequate clinical responses.
Interventions
- DRUG Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2022-08-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04306965
The ClinicalTrials.gov registry entry for NCT04306965 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apremilast is the first listed.
NCT04306965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04306965 about?
NCT04306965 is a clinical study titled "Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab". Open label phase 2 investigational study of efficacy and safety of apremilast 30 mg twice a day (BID) in chronic atopic dermatitis when added to the FDA approved treatment dupilumab for atopic dermatitis that is not providing adequate clinical responses.
What is the current status of trial NCT04306965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2020-08-01. Estimated completion is 2022-08-18.
What interventions are being tested in trial NCT04306965?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT04306965?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.